Recent advances in genetics have had little impact on the day-to-day practice of orthopaedics. This situation is likely to change rapidly as the huge volume of new information about the role of genes in normal development and variation, in ageing, repair and susceptibility to disease, and in the aetiology and pathogenesis of musculoskeletal diseases is appreciated clinically. There is new information concerning somatic gene therapy and the therapeutic uses of proteins produced by recombinant DNA technology.
The escalating advances in genetic knowledge are the result of rapid, worldwide expansion in small and large projects involving many species. Automation and the use of commercially available analytical kits allow even the smallest laboratory to make impressive progress in research. The Human Genome Project involving the sequencing of the three billion nucleotide base pairs of the human genome is expected to be completed within the next few years, well ahead of the original target of 2005. 1 Complete sequences of the eukaryotic genomes of other species such as the fruit fly (Drosophila melanogaster), the round worm (Caenorhabditis elegans) and several strains of mice will be completed soon. 2 These last three studies will provide complementary data to the Human Genome Project and will facilitate the identification of all of the genes of the eukaryotic human genome. A massive amount of work will, however, be needed to determine the function and regulation of each gene as well as its role in normal development, susceptibility to disease and the pathogenesis of diseases.
In the near future it should be possible to describe the complete sequences of genetic events which are involved in the normal development of the skeleton. The consequences of naturally-occurring and induced mutations in fruit flies, worms, frogs, fish and mice, and of naturally-occurring mutations in man, have already been used to identify many of the relevant genes. [3] [4] [5] In studies involving species other than man, each gene of interest may be underexpressed by deleting it, abnormally expressed by altering its sequence of protein coding, overexpressed by adding additional copies of the gene or ectopically expressed by introducing it into abnormal sites. [3] [4] [5] Such studies have provided new insights into the genetic events that direct the normal formation of the axial skeleton and limbs. [3] [4] [5] Identification of all of the genes involved in the normal development of the skeleton is of fundamental importance in orthopaedics. Mutations of some of these genes will be responsible for the many thousands of single-gene disorders of skeletal development that are listed in the database on Online Mendelian Inheritance of Man (http:/ /www.ncbi.nlm.nih.gov/Omim/). Familiar examples include mutations of the type-I collagen genes in osteogenesis imperfecta, the fibrillin-1 gene in the Marfan syndrome and the fibroblast growth factor receptor 3 gene in achondroplasia. Mutations of other genes involved in normal skeletal development may produce benign and malignant tumours. Examples include the p53 tumour protein 6 and retinoblastoma genes in osteosarcomas, 7 the exostosis genes, EXT1 and EXT2, in multiple osteochondromas 8 and the guanine nucleotide-binding protein stimulatory subunit gene, GNAS1, in monostotic and polyostotic fibrous dysplasia. 9 In each of these examples it is likely that the resulting phenotypes are determined by the combined effects of the principal single-gene mutation, modifier genes and environmental factors. The multifactorial nature of single-gene disorders helps to explain the marked variability in clinical phenotypes observed in individuals who carry the same mutation. For example, some affected members of a family with osteogenesis imperfecta may have abnormally blue sclerae and no fractures while others have blue sclerae and numerous fractures. The interactions of many genes, as well as the influence of environmental factors, also appear to determine quantitative skeletal traits such as bone mass. 10 Complex genetic analyses of in bred strains of mice which differ in their bone masses are providing new information about the development, turnover and morphology of bone. 10 The results of these studies should facilitate genetic analyses of familial and sporadic forms of osteoporosis in man.
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There are many other multifactorial disorders of the skeleton which are currently being investigated such as complex genetic analyses of sibling pairs with osteoarthritis 12 and of families with club feet. 13 Progress of these and related studies will be aided by the new DNA sequence and gene data that are added to the public databases each day and by genetic studies of animal models of these disorders. Chromosomal disorders are also being studied intensely. Modern cytogenetics has revealed increasing detail about chromosomal rearrangements while detailed DNA analyses are providing new information about the genes responsible for the diverse clinical features.
14 Similar studies of chromosomal anomalies in malignant tumours have revealed tumour suppresser and enhancer genes. 6 There are major challenges ahead as the enormous amounts of new genetic information concerning the musculoskeletal system become available. One is the availability of easy access to the relevant information for orthopaedic surgeons and patients and another is the ability of orthopaedic surgeons to keep up-to-date with the referral services available for DNA testing and genetic counselling. The latter is important and includes informed consent for DNA testing as well as the confidentiality and interpretation of results. A third challenge is the ability to use the new information to improve the prevention and treatment of genetic disorders of the musculoskeletal system. Somatic gene therapy and other strategies for correcting genetic disorders have great potential but are in their infancy. 15, 16 The identification of genes which produce proteins that have important biological actions in the musculoskeletal system offers potential for new therapies in many orthopaedic conditions. An example is the use of genes which encode growth factors that promote tissue regeneration after injury or other diseases. 17 Recombinant proteins, produced after the introduction of the relevant human DNA sequences into cells or whole organisms, such as bacteria or animals, are likely to become commonplace. Orthopaedic surgeons can look forward to being able to administer recombinant proteins to promote regeneration of tissues selectively or to modify other disease processes. Treatment may also be targeted to specific parts of the body by the direct injection of genetically modified somatic cells from the patient, for example synovial cells or chondrocytes into a joint or fibroblasts into tendon. 18, 19 Alternatively, stromal stem cells from the patient's bone marrow may be modified in vitro so that they will express the biologically active protein in specific tissues when reinfused into the patient. 15, 16, 20 New approaches to the development of more specific and effective methods of curing aggressive benign and malignant tumours of the musculoskeletal system are likely to include the use of recombinant proteins and genetically modified somatic and tumour cells. 21, 22 Complete sequences of the genomes of many pathogenic micro-organisms of importance in the musculoskeletal system have already been published. To date over 400 completely sequenced micro-organisms are available in the public databases. One of the most important recent additions is the complete 4.4 million DNA base pairs of Mycobacterium tuberculosis. 23 New vaccines and therapeutic agents to prevent and treat infections can be expected to have a major impact on orthopaedics. In summary, genetics in orthopaedics is not limited to the numerous but rare single-gene disorders and chromosomal disorders or to the more common multifactorial disorders of the musculoskeletal system, but includes all of the genetic steps that are involved in all aspects of normal development, susceptibility to disease and the pathogenesis of musculoskeletal diseases. It also involves the therapeutic uses of recombinant gene products, related pharmaceuticals and somatic gene therapy. Major changes in the practice of adult and paediatric orthopaedics can be expected to accompany the incorporation of the new genetic knowledge into clinical orthopaedics.
